Key Details About Cagrilintide
-
- What it is: A long-acting, human amylin analogue that acts on receptors in the brain to reduce appetite.
- Mechanism of Action: It functions by mimicking the hormone amylin, which is released by the pancreas to regulate food intake and slow gastric emptying.
- Key Benefits (Clinical Trials):
- Monotherapy: In phase 3 trials, it demonstrated significant weight reduction.
- Combination Therapy (CagriSema): The combination of 2.4 mg cagrilintide and 2.4 mg semaglutide (CagriSema) showed superior results, with studies showing 20.4% body weight loss over 68 weeks.Diabetes management: Research also indicates effectiveness in reducing blood glucose.
- Side Effects: The most common adverse events are gastrointestinal, including nausea (up to 50% of patients), vomiting, diarrhea, constipation, and abdominal pain.
- Administration: It is designed for once-weekly subcutaneous injection.
Key Aspects of Retatrutide:
-
- Average Weight Loss: Phase 2 trials showed up to 17.5% mean weight reduction at 24 weeks, while 48-week, 12 mg doses showed roughly 22.8–24.2% weight reduction
. Phase 3 data indicates average weight loss of up to 24%
-
.Uses: It is being studied for chronic weight management (obesity or overweight with comorbidities) and Type 2 diabetes.
- Average Weight Loss: Phase 2 trials showed up to 17.5% mean weight reduction at 24 weeks, while 48-week, 12 mg doses showed roughly 22.8–24.2% weight reduction
- Mechanism: Unlike single-agonist drugs like Semaglutide (Ozempic), Retatrutide acts on three receptors (GLP-1, GIP, and Glucagon) to decrease appetite, slow gastric emptying, and increase energy expenditure.
- Potential Side Effects: Similar to other GLP-1 receptor agonists, common side effects are gastrointestinal, including nausea, diarrhea, vomiting, and constipation, especially when starting or increasing the dosage. Other reports include a slightly elevated heart rate.
Be the first to review “Reta & Cagri Combo”
Related products
Sale!
Sale!
Reviews
There are no reviews yet.